上海交通大学学报（医学版）

上海交通大学学报（医学版）

• 综述 • 上一篇    下一篇

二甲双胍与胰腺癌治疗的研究现状

王一玮，郑磊贞   

  1. 上海交通大学医学院附属新华医院肿瘤科， 上海 200092
  • 出版日期:2014-11-28 发布日期:2014-12-02
  • 作者简介:王一玮（1990—）， 女， 硕士生; 电子信箱: wywxrbnm@163.com。

Advances of metformin and treatment of pancreatic cancer

WANG Yi-wei, ZHENG Lei-zhen   

  1. Department of Oncology, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200092, China
  • Online:2014-11-28 Published:2014-12-02

PDF (PC)

1407

摘要：

二甲双胍作为治疗糖尿病的一线药物，不仅有降血糖的作用，还有抗肿瘤的生物学效应。临床流行病学研究表明，2型糖尿病可增加罹患胰腺癌的风险；因此，二甲双胍在治疗和预防胰腺癌方面的作用受到了人们越来越多的关注。流行病学研究数据揭示了二甲双胍可降低糖尿病患者胰腺癌的发生率，这给胰腺癌的治疗提供了新的思路。该文从流行病学和分子机制等方面对二甲双胍与胰腺癌治疗的关系予以综述。

关键词: 二甲双胍, 胰腺癌, 流行病学, AMPK/mTOR轴, 胰岛素样生长因子受体, 细胞周期

Abstract:

As the firstline drug for the treatment of diabetes, metformin not only has the effect of reducing blood glucose, but also has biological effects of antitumor. Clinical epidemiological studies show that type 2 diebetes can increase the risk of pancreatic cancer. Therefore, metformin has received more and more attention on the treatment and prevention of pancreatic cancer. The epidemiological data reveals that metformin can reduce the incidence of pancreatic cancer of patients with diabetes, which might be a new strategy for the treatment of pancreatic cancers. This paper reviews the relationships between metformin and the treatment of pancreatic cancer in terms of epidemiology and molecular mechanisms involved.

Key words: metformin, pancreatic cancer, epidemiology, AMPK/mTOR axis, insulin-like growth factor receptor, cell cycle